Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 763 across all filing types
Latest filing 2021-01-26 AGM Information
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
AGM Information Classification · 99% confidence The document is titled "Notice of Extraordinary General Meeting in Karolinska Development AB (publ)" and details the procedures for shareholders to participate in the EGM via advance voting, including record dates, notification deadlines, and proxy instructions. It also outlines the proposed agenda items, which include the election of the chairman and directors, and crucially, the proposal regarding principles for remuneration to executive management (Item 8). The content focuses entirely on the logistics and proposals for a shareholder meeting, specifically an Extraordinary General Meeting (EGM). This strongly aligns with the purpose of materials distributed to shareholders in preparation for a general meeting, which is covered by the Proxy Solicitation & Information Statement (PSI) definition, or potentially AGM-R if the distinction between AGM and EGM is ignored, but PSI is more precise for meeting notices and voting materials. Since it is an EGM notice detailing voting procedures and proposals, PSI is the most appropriate classification.
2021-01-26 English
Karolinska Development ökar det bokförda värdet av innehavet i Umecrine Cognition med SEK 234 miljoner
Net Asset Value Classification · 99% confidence The document is a press release dated December 29, 2020, announcing a significant increase in the book value of an investment (Umecrine Cognition) based on an external valuation following positive Phase 2a clinical trial results. It details the financial impact (SEK 234 million positive effect for Q4 2020) and provides context on the underlying asset's development plan. This type of announcement, focusing on a specific financial event, valuation change, or material development outside of routine periodic reporting (like 10-K or IR), fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a general disclosure. However, since it is a specific announcement regarding the valuation of an investment portfolio holding, which impacts the company's capital structure/asset value, and is not a standard earnings release (ER) or interim report (IR), it is most closely aligned with 'Capital/Financing Update' (CAP) as it directly relates to the valuation of assets. Given the options, 'CAP' (Capital/Financing Update) covers changes in capital structure or significant asset valuation adjustments that impact the balance sheet, which this valuation increase represents. It is a specific corporate action announcement, not a general regulatory filing (RNS) or a report itself (like 10-K or AR). The length (5026 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2020-12-29 Swedish
Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
Earnings Release Classification · 99% confidence The document is a press release dated December 29, 2020, announcing a specific financial event: Karolinska Development increasing the book value of its holding in Umecrine Cognition by SEK 234 million based on positive clinical trial results and an external valuation. This is a material corporate event announcement related to asset valuation and portfolio updates, not a full annual report (10-K), quarterly report (IR), or a formal earnings release (ER) which typically covers overall company performance. It is a specific announcement regarding capital/financing activities related to an investment holding, which aligns best with the 'Capital/Financing Update' (CAP) category, as it directly impacts the book value and capital structure perception of the investment company. It is too specific for a general Regulatory Filing (RNS) and does not fit other categories like DIRS, DIV, or M&A. Q4 2020
2020-12-29 English
Karolinska Development's portfolio company Aprea Therapeutics reports results from Phase 3 study of eprenetapopt in MDS
Legal Proceedings Report Classification · 99% confidence The document reports on the results of a Phase 3 clinical study for a portfolio company (Aprea Therapeutics) and is issued by the parent company (Karolinska Development AB). It details clinical outcomes (CR rates, statistical significance) related to a drug (eprenetapopt) and concludes with a statement that the information is being made public pursuant to the EU Market Abuse Regulation. This structure—announcing specific, material, non-financial operational/clinical news that impacts the company's value—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (10-K, IR, ER). Since it is a material announcement that doesn't fit ER (Earnings Release, which focuses on financial metrics) or LTR (Legal Proceedings), the most appropriate general category for significant, non-financial regulatory disclosures that don't fit elsewhere is Regulatory Filings (RNS). It is not a transcript (CT), an investor presentation (IP), or a formal financial report (IR/10-K).
2020-12-28 English
Karolinska Developments portföljbolag Aprea Therapeutics rapporterar resultat från fas 3-studie av eprenetapopt i MDS
Legal Proceedings Report Classification · 99% confidence The document is a press release from Karolinska Development AB announcing clinical trial results for its portfolio company, Aprea Therapeutics. The core content discusses the outcome of a Phase 3 study (failure to meet the primary endpoint for complete remission) and includes quotes from the CEO regarding next steps. This type of announcement, detailing specific clinical trial data and its immediate implications, is characteristic of an Earnings Release (ER) or a general corporate update related to product development. Since it is an announcement of key operational/clinical results rather than a full quarterly/annual report (10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category is Earnings Release (ER), as clinical trial updates often accompany or substitute for traditional earnings highlights in biotech/pharma. It is a direct announcement of performance metrics, even if clinical rather than purely financial.
2020-12-28 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT Jan-Sep 2020' (Interim Report Jan-Sep 2020) and contains comprehensive financial data, including income statements, balance sheet items, and detailed management commentary on business performance and portfolio companies. It is not a short announcement, but a full interim report covering a period shorter than a full fiscal year. 9M 2020
2020-11-11 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.